Company Overview
TWi Biotechnology, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics in dermatology and central nervous system (“CNS”) disorders through the US FDA's 505(b)(2) regulatory pathway. Our portfolio features 3 clinical-stage drug candidates targeting multiple indications, alongside a growing pipeline of projects under early-stage development. Based in Taipei, Taiwan, we operate with a global perspective, conducting international clinical studies and collaborating with world-class consultants and key opinion leaders. Our shares are publicly traded in Taiwan (ticker: 6610.TWO).
Mission
To deliver safe, effective, and convenient treatment, improve the patients' quality of life, and create value for our stakeholders.
Goals
- Distinguishing ourselves as a premier biopharmaceutical company with global influence.
- Developing “first-in-class” and “best-in-class” therapeutics that address critical unmet medical needs;
- Building a diversified, risk-balanced portfolio to ensure sustainable long-term growth for our shareholders.
Therapeutic Areas
Prior to 2025, our development efforts were focused on rare disease and dermatological disorders. Upon merging with Dukang Pharmaceuticals, Inc. in September 2025, our therapeutic footprint has expanded from dermatology into central nervous system (“CNS”).
- Dermatology: A therapeutic area that focuses on diseases of the skin, hair, and nails, encompassing inflammatory, autoimmune, genetic, and infectious conditions. Major indications include psoriasis, atopic dermatitis, vitiligo, alopecia areata and rare disorders such as epidermolysis bullosa. Competition is intense in biologics, while opportunities remain strong for differentiated topical, small-molecule, and rare-disease therapies offering improved safety, effectiveness, and convenience of use.
- Central Nervous System, CNS: A therapeutic area that addresses disorders of the brain and mental disorder, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. With high disease burden and chronic treatment needs, CNS is one of the largest pharmaceutical markets globally. Given the CNS field remains a largely unmet medical need, successful innovation in novel mechanisms and enhanced patient compliance commands significant commercial value.
Targeting Both Rare and High-Prevalence Diseases
We pursue a two-pronged strategy, targeting both rare diseases and high-prevalence conditions. While we are proceeding with a global Phase 2/3 clinical trial on AC-203 for the treatment of Epidermolysis Bullosa Simplex (a rare dermatologic disease) in full speed, we are advancing the development of innovative therapeutics on several high-prevalence diseases such as Alopecia Areata and Depression in parallel. This dual-track approach allows us to build a balanced portfolio with diversified risks while optimizing the long-term value of this company.